The Journal of Clinical Hypertension (May 2022)

Comparative effectiveness of generic nifedipine versus Adalat long‐acting nifedipine for hypertension treatment: A multi‐institutional cohort study

  • Ying‐Chang Tung,
  • Chia‐Pin Lin,
  • Fu‐Chih Hsiao,
  • Chien‐Te Ho,
  • Hsu Tzyy‐Jer,
  • You‐Chia Chu,
  • Wen‐Jone Chen,
  • Pao‐Hsien Chu

DOI
https://doi.org/10.1111/jch.14478
Journal volume & issue
Vol. 24, no. 5
pp. 621 – 629

Abstract

Read online

Abstract This retrospective multi‐institutional database analysis aimed to evaluate the blood‐pressure‐lowering efficacy and clinical outcomes of a generic versus brand‐name nifedipine for hypertension management. A total of 12 693 patients who were prescribed a generic or brand‐name nifedipine between January 1, 2011, and December 31, 2018, were identified from the Chang Gung Research Database of Chang Gung Memorial Hospitals, Taiwan. Among them, 2112 (21.4%) were prescribed generic nifedipine. After propensity score matching, both the generic and brand‐name groups consisted of 2102 patients. At a mean follow‐up of 3 years, the changes in office systolic (p for interaction = .791) and diastolic blood pressure (p for interaction = .689) did not differ significantly between the patients who received the generic and the brand‐name nifedipine. There was no significant difference between the two study groups regarding the composite of all‐cause mortality, acute myocardial infarction, stroke, coronary revascularization, or hospitalization for heart failure (hazard ratio 0.98, 95% confidence interval 0.85–1.13; p = .774). In conclusion, the generic nifedipine was comparable to its brand‐name counterpart regarding office blood pressure reduction and the composite cardiovascular outcome for the treatment of patients with hypertension.

Keywords